Stefani Spranger’s work is focused on uncovering why some tumors evade the immune system’s attack. For example, her latest research, published in Cancer Immunology Research, reveals that lung cancer cells expressing SOX2 can block CD8+ T cells, undermining checkpoint blockade therapy. “By understanding these resistance mechanisms, we can develop smarter immunotherapies to outmaneuver cancer,” says Spranger.